Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19700447 | 0.85 | POLB (0.72) | POLBKCNN3LMNATP53NPSR1 | |
| SCHEMBL19690945 | 0.82 | POLB (0.63) | POLBKCNN3LMNATP53NPSR1 | |
| SCHEMBL25192892 | 0.76 | POLB (0.83) | POLBKCNN3LMNATP53NPSR1 | |
| SCHEMBL19691022 | 0.75 | ADORA2A (0.55) | POLBKCNN3ADORA2AALOX15 | |
| SCHEMBL15573286 | 0.74 | POLB (1.00) | POLBKCNN3LMNATP53NPSR1 | |
| SCHEMBL19700443 | 0.74 | POLB (0.54) | POLBKCNN3LMNATP53NPSR1 | |
| SCHEMBL25192975 | 0.74 | KCNN3 (0.84) | POLBKCNN3LMNATP53NPSR1 | |
| SCHEMBL19690906 | 0.73 | RAB9A (0.36) | LMNATP53GAAL3MBTL1 | |
| SCHEMBL3577746 | 0.72 | MAPT (0.57) | POLBKCNN3LMNATP53ALOX15 | |
| SCHEMBL25186989 | 0.71 | POLB (0.80) | POLBKCNN3LMNATP53NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | POLB 4779/4885KCNN3 15/4885LMNA 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.